TwinBeech Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

TwinBeech Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-55,249	Closed	-$22.2M	–	991
2024 Q4	$22.2M	Buy	+55,249	New	+$25.6M	0.38%	89
2023 Q1	–	Sell	-192,626	Closed	-$55.6M	–	912
2022 Q4	$55.6M	Buy	+192,626	New	+$58.7M	1.06%	11
2022 Q1	–	Sell	-7,909	Closed	-$1.74M	–	757
2021 Q4	$1.74M	Sell	7,909 -59,347	-88%	-$11.5M	0.1%	255
2021 Q3	$12.2M	Buy	67,256 +45,061	+203%	+$8.8M	0.86%	21
2021 Q2	$4.47M	Buy	+22,195	New	+$4.64M	0.54%	56
2020 Q1	–	Sell	-7,050	Closed	-$1.54M	–	493
2019 Q4	$1.54M	Buy	+7,050	New	+$1.43M	0.45%	63

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

TwinBeech Capital's VRTX Position: Q1 2025 in Review

TwinBeech Capital sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 55,249 shares — an estimated $22.2M sold.

TwinBeech Capital first reported a position in VRTX in Q4 2019 and held it in 6 quarters. The position peaked at $55.6M in Q4 2022. 1,612 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

TwinBeech Capital reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
TwinBeech Capital sold 55,249 Vertex Pharmaceuticals shares in Q1 2025, an estimated $22.2M.
TwinBeech Capital first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 6 quarters.
TwinBeech Capital's Vertex Pharmaceuticals position peaked at $55.6M in Q4 2022.
1,612 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on TwinBeech Capital's 13F filing for Q1 2025, filed 15 May 2025.